Cure Pharmaceutical to acquire cannabinoid-based pipeline from Therapix Biosciences
OXNARD, Calif. – Cure Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences, a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the related conditions. These assets include several clinical drug candidates as well as two pre-clinical drug candidates. Cure will issue shares
